½ÃÀ庸°í¼­
»óǰÄÚµå
1451538

¼¼°èÀÇ ½Å°æ°ú ±â±â ½ÃÀå º¸°í¼­ : Á¦Ç°, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°(2024-2032³â)

Neurology Devices Market Report by Product, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 139 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ½Å°æ°ú ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 134¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 2024-2032³â°£ 7.1%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇϸç 2032³â±îÁö 251¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖ½À´Ï´Ù.

½Å°æÇÐÀº ½Å°æ°è Áúȯ°ú Àå¾Ö¸¦ ´Ù·ç´Â ÀÇÇÐÀÇ ÇÑ ºÐ¾ßÀÔ´Ï´Ù. ½Å°æÇп¡¼­ ³Î¸® »ç¿ëµÇ´Â ÀåÄ¡¿¡´Â ¿©·¯ À¯ÇüÀÌ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, õ°ñ ½Å°æ Àڱرâ´Â Ç㸮 ºÎÀ§¿¡ Àִ ǥÀû õ°ñ ½Å°æ¿¡ Àü±â ÀÚ±ØÀ» º¸³»´Â ¹æ½ÄÀ¸·Î ÀÛµ¿ÇÕ´Ï´Ù. ³úô¼ö¾×(CSF) °ü¸® ÀåÄ¡´Â ³úô¼ö¾×ÀÇ È帧À» À¯ÁöÇÏ°í ³ú¿¡¼­ °úµµÇÑ ¾×ü¸¦ ¹èÃâÇÏ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÇÑÆí, ³ú½ÉºÎÀڱرâ´Â ³úÀÇ Æ¯Á¤ Ç¥Àû ºÎÀ§¿¡ Àü±â ÀÚ±ØÀ» º¸³»´Â ÀÇ·á±â±â¸¦ À̽ÄÇÏ¿© ½Ã¼ú ¼öÇàÀ» µ½½À´Ï´Ù. ÀÌ ÀåÄ¡´Â º¹ÀâÇÑ Áúº´À» Ä¡·áÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú °­¹ÚÀå¾Ö, ÆÄŲ½¼º´, ±Ù±äÀåÀÌ»óÁõ, ¸¸¼ºÅëÁõ, º»Å¼º ÁøÀü, ´ëÀαâÇÇÁõ, ¿ì¿ïÁõ µî ´Ù¾çÇÑ ½Å°æÁúȯÀÇ Ä¡·á¿¡ ³Î¸® Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

½Å°æ°ú ±â±â ½ÃÀå µ¿Çâ :

½ÃÀåÀº ÁÖ·Î ÇコÄÉ¾î ºÎ¹®ÀÇ Å« ÆøÀÇ ¼ºÀå¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ´õºÒ¾î Àü ¼¼°èÀûÀ¸·Î ½Å°æ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ Á¦Ç° ¼ö¿ä¿¡ Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. ³ëÀÎ Àα¸ Áõ°¡¿Í ³ëÀεéÀÇ ³úÁ¹Áß°ú °°Àº ½Å°æÇ÷°ü ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â ½Å°æÇÐÀû ÀåÄ¡ÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áö¼ÓÀûÀÎ ½Å°æÇÐÀû ±â±âÀÇ ±â¼ú ¹ßÀü°ú ÃÖ¼Òħ½À(MI) ¼ö¼ú¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ¼ö¿ä´Â Àü ¼¼°èÀûÀ¸·Î Áß¿äÇÑ ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ÀÇ·áºñ ÁöÃâ Áõ°¡, ¼¼°è ÀÇ·á±â±â Á¦Á¶¾÷üµéÀÇ ´ë±Ô¸ð ÅõÀÚ, ½Å°æ Ä¡·á ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ Á¶»ç °³¹ß(R&D) µîÀÌ ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • 2023³â ¼¼°è ½Å°æ°ú ±â±â ½ÃÀå ±Ô¸ð´Â?
  • 2024³âºÎÅÍ 2032³â±îÁö ¼¼°è ½Å°æ°ú ±â±â ½ÃÀå ¼ºÀå·ü Àü¸ÁÀº?
  • ½Å°æ°ú ±â±â ¼¼°è ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº?
  • Äڷγª19°¡ ¼¼°è ½Å°æ°ú ±â±â ½ÃÀå¿¡ ¹ÌÄ£ ¿µÇâÀº?
  • ½Å°æ°ú ±â±â ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¦Ç°º° ºÐ·ù´Â?
  • ¼¼°è ½Å°æ°ú ±â±â ½ÃÀå¿¡¼­ÀÇ ÃÖÁ¾ »ç¿ëÀÚº° ºÐ·ù´Â?
  • ½Å°æ°ú ±â±â ¼¼°è ½ÃÀå ÁÖ¿ä Áö¿ªÀº?
  • ½Å°æ°ú ±â±â ¼¼°è ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ½Å°æ°ú ±â±â ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ºÐ¼® : Á¦Ç°º°

  • ½Å°æ ÀÚ±Ø ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ³ú½Å°æ¿Ü°ú¿ë ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ÁßÀçÀû ½Å°æ°ú ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ³úô¼ö¾×(CSF) °ü¸® ±â±â
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ½Å°æ Ŭ¸®´Ð
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ºÐ¼® : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ij³ª´Ù
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÀϺ»
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Àεµ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Çѱ¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • È£ÁÖ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • Àεµ³×½Ã¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • À¯·´
    • µ¶ÀÏ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÇÁ¶û½º
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ¿µ±¹
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ÀÌÅ»¸®¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ½ºÆäÀÎ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ·¯½Ã¾Æ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ¸ß½ÃÄÚ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
    • ±âŸ
      • ½ÃÀå µ¿Çâ
      • ½ÃÀå ¿¹Ãø
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ºÐ¼® : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦9Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦10Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦11Àå PorterÀÇ Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦12Àå °¡°Ý ºÐ¼®

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • Abbott Laboratories
    • B. Braun
    • Boston Scientific Corporation
    • Integra LifeSciences
    • LivaNova PLC
    • Medtronic plc
    • Nihon Kohden Corporation
    • Penumbra Inc.
    • Stryker Corporation
LSH 24.04.16

The global neurology devices market size reached US$ 13.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 25.1 Billion by 2032, exhibiting a growth rate (CAGR) of 7.1% during 2024-2032.

Neurology is a stream of medical science that deals with diseases and disorders of the nervous system. There are numerous types of devices that are widely used in neurology. For instance, sacral nerve stimulation devices function by sending electrical impulses to the targeted sacral nerves located in the lower back. On the other hand, cerebrospinal fluid management devices maintain the cerebrospinal fluid flow and drain excess fluid from the brain. In line with this, interventional devices use radiology and catheters to diagnose the medical conditions present in the central nervous system, whereas deep brain stimulation devices aid in performing procedures by implanting a medical device that sends electrical impulses to specific target areas in the brain. These devices are instrumental in treating complex disorders. As a result, they find widespread applications in the treatment of numerous neurological disorders, such as obsessive-compulsive disorder, Parkinson's disease, dystonia, chronic pain, essential tremor, and major depression.

Neurology Devices Market Trends:

The market is primarily driven by considerable growth in the healthcare sector. In addition to this, the growing prevalence of neurological disorders across the globe is significantly contributing to the product demand. The increasing geriatric population and the rising incidences of neurovascular conditions, such as stroke, among the elderly are further propelling the adoption of neurology devices, thereby augmenting the growth of the market. Moreover, continual technological advancements in neurology devices and the widespread demand for minimally invasive (MI) surgeries are also acting as significant growth-inducing factors across the globe. Some of the other factors providing an impetus to the market growth include the expanding healthcare expenditure, huge investments made by global medical device manufacturers and extensive research and development (R&D) in the field of neurotherapy.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global neurology devices market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product and end user.

Breakup by Product:

Neurostimulation Devices

Neurosurgery Devices

Interventional Neurology Devices

Cerebrospinal Fluid Management Devices

Others

Breakup by End User:

Hospitals

Ambulatory Surgery Centers

Neurology Clinics

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, B. Braun, Boston Scientific Corporation, Integra LifeSciences, LivaNova PLC, Medtronic plc, Nihon Kohden Corporation, Penumbra Inc. and Stryker Corporation.

Key Questions Answered in This Report

  • 1. What was the size of the global neurology devices market in 2023?
  • 2. What is the expected growth rate of the global neurology devices market during 2024-2032?
  • 3. What are the key factors driving the global neurology devices market?
  • 4. What has been the impact of COVID-19 on the global neurology devices market?
  • 5. What is the breakup of the global neurology devices market based on the product?
  • 6. What is the breakup of the global neurology devices market based on the end user?
  • 7. What are the key regions in the global neurology devices market?
  • 8. Who are the key players/companies in the global neurology devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neurology Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Neurostimulation Devices
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Neurosurgery Devices
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Interventional Neurology Devices
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cerebrospinal Fluid Management Devices
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Ambulatory Surgery Centers
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurology Clinics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Abbott Laboratories
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 B. Braun
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 SWOT Analysis
    • 13.3.3 Boston Scientific Corporation
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Integra LifeSciences
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 LivaNova PLC
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 Medtronic plc
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Nihon Kohden Corporation
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Penumbra Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Stryker Corporation
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦